-
公开(公告)号：EP2480198B1
公开(公告)日：2016-03-09
申请号：EP10759786.6
申请日：2010-09-21
申请人： Baxalta GmbH , Baxalta Incorporated
CPC分类号： A61K38/4886 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K47/02 , A61K47/10 , A61K47/183 , A61K47/22 , A61K47/26 , C12Y304/24087
摘要： The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
-
公开(公告)号：EP2968455B1
公开(公告)日：2019-07-17
申请号：EP14718870.0
申请日：2014-03-14
申请人： Baxalta Incorporated , Baxalta GmbH
-
13.发明公开
公开(公告)号：EP3388529A1
公开(公告)日：2018-10-17
申请号：EP18173838.6
申请日：2009-12-03
申请人： Baxalta GmbH , Baxalta Incorporated
发明人： VARADI, Katalin , ROTTENSTEINER, Hanspeter , TURECEK, Peter , SCHWARZ, Hans-Peter , SCHREINER, Jutta
CPC分类号： G01N33/86 , C12Q1/37 , C12Q1/56 , G01N33/573 , G01N2333/755 , G01N2333/96486 , G01N2800/224 , G01N2800/52
摘要： The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
-
公开(公告)号：EP2791675B1
公开(公告)日：2018-04-25
申请号：EP12820994.7
申请日：2012-12-13
申请人： Baxalta GmbH , Baxalta Incorporated
IPC分类号： G01N33/53 , G01N33/564 , A61K39/395 , G01N33/543
CPC分类号： G01N33/6854 , G01N33/54393 , G01N33/564 , G01N2333/4709
摘要： Methods for detecting or capturing low-avidity autoantibodies in a biological sample are provided. Target antigen used to assay for the low-avidity autoantibodies of interest is immobilized on a solid phase. The biological sample is contacted under low conductivity condition with the target antigen for which the autoantibodies has specific binding affinity. Binding of the target antigen to the autoantibodies of interest in the biological sample is then detected to ascertain the presence or concentration of the autoantibodies of interest.
-
公开(公告)号：EP3167897A1
公开(公告)日：2017-05-17
申请号：EP15203085.4
申请日：2010-09-21
申请人： Baxalta GmbH , Baxalta Incorporated
CPC分类号： A61K38/4886 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K47/02 , A61K47/10 , A61K47/183 , A61K47/22 , A61K47/26 , C12Y304/24087
摘要： The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
摘要翻译： 本发明涉及具有增强的或期望的性质的ADAMTS13的制剂。 如此，本发明提供适合药物施用的ADAMTS13的液体和冻干制剂。 除其他方面外，本发明还提供了治疗受试者中与VWF和/或ADAMTS13功能障碍相关的各种疾病和病症的方法。 本文还提供了包含用于治疗各种疾病和病症的ADAMTS13制剂的试剂盒。
-
16.发明授权METHOD FOR REDUCING THE THROMBOEMBOLIC POTENTIAL OF A PLASMA-DERIVED IMMUNOGLOBULIN COMPOSITION 有权VERFAHREN ZUR REDUZIERUNG DES THROMBOEMBOLISCHEN电位EINER AUS PLASMA GEWONNENEN IMMUNOGLOBULINZUSAMMENSETZUNG
公开(公告)号：EP2748193B1
公开(公告)日：2017-02-01
申请号：EP12768938.8
申请日：2012-08-27
申请人： Baxalta GmbH , Baxalta Incorporated
发明人： TESCHNER, Wolfgang , BUTTERWECK, Harald, Arno , KOELBL, Bernhard , GNAUER, Lucia , SCHWARZ, Hans-Peter
IPC分类号： C07K16/06
CPC分类号： C07K16/065
-
17.发明公开TREATMENT OF ALZHEIMER'S DISEASE SUBPOPULATIONS WITH POOLED IMMUNOGLOBULIN G 有权百灵达茉莉花 - 阿尔茨海默 - 多囊卵单分枝杆菌GEPOOLTEM IMMUNGLOBULIN G
公开(公告)号：EP2994160A1
公开(公告)日：2016-03-16
申请号：EP14730660.9
申请日：2014-05-05
申请人： Baxalta Incorporated , Baxalta GmbH
IPC分类号： A61K39/00
CPC分类号： C07K16/18 , A61K38/47 , A61K39/39516 , A61K2039/505 , C07K16/06 , C07K16/065 , G01N33/6896
摘要： The present invention provides, among other aspects, methods for the treatment of Alzheimer's disease in a subject in need thereof, the method including administration of a therapeutically effective amount of a pooled human immunoglobulin G (IgG) composition to a subject with moderately severe Alzheimer's disease, a subject carrying an ApoE4 allele, or both, where the amount of pooled human IgG is from 300 mg/kg to 800 mg/kg body weight of the subject per two week period, and where the amount is administered in one or more doses during the two week period after initiation of a therapeutic regimen. Also provided, are methods for selecting a treatment regimen for a subject with Alzheimer's disease, including diagnosing the severity of the Alzheimer's disease, determining if the subject carries an APOE4 allele, or both, and assigning a treatment regimen including administration of pooled human immunoglobulin G and/or an anti-beta amyloid monoclonal antibody.
摘要翻译： 除其他方面外，本发明还提供了在有需要的受试者中治疗阿尔茨海默氏病的方法，所述方法包括将治疗有效量的合并的人免疫球蛋白G（IgG）组合物施用于具有中度严重阿尔茨海默病的受试者 ，携带ApoE4等位基因或两者的受试者，其中合并的人IgG的量为每两周的受试者的300mg / kg至800mg / kg体重，并且其中所述量以一个或多个剂量 在开始治疗方案后的两周期间。 还提供了用于选择患有阿尔茨海默病的受试者的治疗方案的方法，包括诊断阿尔茨海默氏病的严重程度，确定受试者是否携带APOE4等位基因或两者，以及分配治疗方案，包括给予合并的人免疫球蛋白G 和/或抗β淀粉样蛋白单克隆抗体。
-
公开(公告)号：EP2350294B1
公开(公告)日：2018-12-05
申请号：EP09752581.0
申请日：2009-10-27
申请人： Baxalta GmbH , Baxalta Incorporated
IPC分类号： C12N15/85 , A01K67/027 , A61K49/00
CPC分类号： A61K49/0008 , A01K67/027 , A01K67/0275 , A01K67/0276 , A01K2217/052 , A01K2217/054 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0306 , A01K2267/0325 , A01K2267/0381 , C12N15/8509
摘要： The invention relates to the development of an animal model for testing various agents in the treatment of a clotting disorder. More specifically, the invention relates to the use of ultra-large molecular weight multimers of von Willebrand factor (VWF) in various mouse strains to induce thrombotic thrombocytopenic purpura (TTP)-like symptoms for the development of a mouse model of TTP. The invention also provides methods for generating such animal disease models and screening methods for identifying biologically active compounds which are effective in the treatment of TTP.
-
公开(公告)号：EP2681553B1
公开(公告)日：2017-05-10
申请号：EP12709015.7
申请日：2012-03-01
申请人： Baxalta GmbH , Baxalta Incorporated
CPC分类号： G01N33/50 , G01N33/92 , G01N2400/00
-
20.发明公开METHODS TO PRODUCE A HUMAN PLASMA-DERIVED IGG PREPARATION ENRICHED IN BRAIN DISEASE-RELATED NATURAL IGGS 审中-公开用于生产IGG从人血浆生产富含脑部疾病有关的自然IGG
公开(公告)号：EP2970377A1
公开(公告)日：2016-01-20
申请号：EP14721128.8
申请日：2014-03-14
申请人： Baxalta Incorporated , Baxalta GmbH
发明人： HOFBAUER, Lucia , BUTTERWECK, Harald Arno , BAUER, Theresa , WEBER, Alfred , TESCHNER, Wolfgang , SCHWARZ, Hans-Peter
CPC分类号： C07K16/18 , A61K2039/507 , B01D15/16 , B01D15/362 , B01D15/363 , B01D15/426 , B01D61/027 , B01D2311/2623 , C07K14/4717 , C07K16/065 , C07K16/2803 , C07K2317/732
摘要： The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-Aβ, anti-RAGE, and anti-α-synuclein antibodies). Advantageously, the methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-brain disease related protein antibodies (e.g., anti-Aβ, anti-RAGE, and anti-α-synuclein antibodies), as also provided here. Methods for the treatment of brain diseases and disorders by administration of plasma-derived IgG compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-Aβ, anti-RAGE, and anti-α-synuclein antibodies), are also provided.
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.03 秒)
